Plus Therapeutics, Inc. (Nasdaq: PSTV) today announced that its state-of-the-art clinical laboratory in Houston, Texas, has successfully earned a Certificate of Accreditation from the Centers for Medicare & Medicaid Services (CMS).

The accreditation follows a planned laboratory audit and confirms the facility’s compliance with the Clinical Laboratory Improvement Amendments (CLIA) — federal quality standards for laboratories performing testing on human specimens. This achievement demonstrates Plus Therapeutics’ commitment to maintaining the highest level of quality, safety, and regulatory compliance in its diagnostic testing services.

“This CMS accreditation reinforces the rigor and precision of our laboratory operations,” said Russell Bradley, President and General Manager. “It ensures that the innovative work we are doing through our CNSide® platform meets the highest federal standards for accuracy and reliability.”

Advancing Precision Diagnostics in Neuro-Oncology

The company’s proprietary CNSide® Cerebrospinal Fluid (CSF) Assay Platform is performed exclusively in its CLIA-certified laboratory. CNSide® provides healthcare providers with a highly sensitive and reliable diagnostic solution designed to improve the management of leptomeningeal metastases (LM) and other complex neuro-oncology conditions.

By earning this CMS accreditation, Plus Therapeutics further strengthens confidence in its testing accuracy, quality assurance systems, and compliance with rigorous federal oversight — key factors for expanding payer adoption and patient access.

Why This Matters

• Quality Assurance: CLIA accreditation sets a recognized gold standard for laboratory testing accuracy and reliability.
• Expanded Access: Accreditation supports broader payer adoption, helping more patients benefit from CNSide® testing.
• Commercial Readiness: This milestone aligns with Plus Therapeutics’ strategic efforts to scale its precision diagnostics offerings.

Learn More

Read the full press release: Plus Therapeutics CMS Accreditation Announcement
Investor Relations: Plus Therapeutics (Nasdaq: PSTV)
Explore CNSide® Diagnostics: CNSide® Official Site